Abstract:Hematologic malignancies, including leukemia, lymphoma, myeloproliferative disorder and plasma cell neoplasia, are genetically heterogeneous and characterized by an uncontrolled proliferation of their corresponding cell lineages in the bone marrow, peripheral blood, tissues or plasma. Although there are many types of therapeutic drugs (e.g., TKIs, chemotherapy drugs) available for treatment of different malignancies, the relapse, drug resistance and severe side effects due to the lack of selectivity seriously limit their clinical application. Currently, although antibody-drug conjugates have been well established as able to target and deliver highly potent chemotherapy agents into cancer cells for the reduction of damage to healthy cells and have achieved success in leukemia treatment, they still also have shortcomings such as high cost, high immunogenicity and low stability. Aptamers are ssDNA or RNA oligonucleotides that can also precisely deliver therapeutic agents into cancer cells through specifically recognizing the membrane protein on cancer cells, which is similar to the capabilities of monoclonal antibodies. Aptamers exhibit higher binding affinity, lower immunogenicity and higher thermal stability than antibodies. Therefore, in this review we comprehensively describe recent advances in the development of aptamer-drug conjugates (ApDCs) with cytotoxic payload through chemical linkers or direct incorporation, as well as further introduce the latest promising aptamers-based therapeutic strategies such as aptamer-T cell therapy and aptamer-PROTAC, clarifying their bright application, development direction and challenges in the treatment of hematologic malignancies.

Aptamers in hematological malignancies and their potential therapeutic implications.

Novel Insights into the Role of Aptamers in the Fight Against Cancer.

The Research Advances of Aptamers in Hematologic Malignancies.

Aptamers: an Emerging Navigation Tool of Therapeutic Agents for Targeted Cancer Therapy

Oligonucleotide Aptamer-Mediated Precision Therapy of Hematological Malignancies

The Landscape of Nucleic-Acid-Based Aptamers for Treatment of Hematologic Malignancies: Challenges and Future Directions

Aptamers, the Nucleic Acid Antibodies, in Cancer Therapy

Progress on Aptamer for Cancer Theranostics

Clinical applications of aptamers and nucleic acid therapeutics in haematological malignancies.

Oligonucleotide Aptamers: New Tools for Targeted Cancer Therapy.

Nucleic acid aptamers in cancer research, diagnosis and therapy.

Aptamer‐Based Cancer Cell Analysis and Treatment

Application and development of aptamer in cancer: from clinical diagnosis to cancer therapy

Aptamers in cancer therapy: problems and new breakthroughs

Aptamer Technology and Its Applications in Bone Diseases

Nucleic Acid Aptamers for Molecular Diagnostics and Therapeutics: Advances and Perspectives.

Clinical applications of nucleic acid aptamers in cancer.

The Application of Aptamers in Cancer Research: an Up-to-date Review.

Oligonucleotide aptamers: Recent advances in their screening, molecular conformation and therapeutic applications

Aptamers: Active Targeting Ligands for Cancer Diagnosis and Therapy

Nucleic Acid Aptamers: an Emerging Frontier in Cancer Therapy